Juvena Therapeutics | $33,500,000 | (Jan 14, 2026)
WithCoverage | $42,000,000 | (Jan 14, 2026)
Allos | $5,000,000 | (Jan 14, 2026)
Alpha-9 Oncology
United States
- Boston, Massachusetts
- 24/10/2024
- Series C
- $175,000,000
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
- Industry Biotechnology Research
- Website https://www.a9oncology.com/
- LinkedIn https://www.linkedin.com/company/a9oncology/
WeatherPromise | $12,800,000 | (Jan 14, 2026)
Nodu | $1,450,000 | (Jan 14, 2026)
Cloudforce | $10,000,000 | (Jan 14, 2026)
Converge Bio | $25,000,000 | (Jan 14, 2026)
JetZero | $175,000,000 | (Jan 14, 2026)
Cytotheryx, Inc. | $60,000,000 | (Jan 13, 2026)
MEDIPOST, Inc. | $140,000,000 | (Jan 13, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)
VelaFi | $20,000,000 | (Jan 13, 2026)